All In Biotech

Drug Trial Radar · NCT07746271

Gestational Hypertension and Preeclampsia Blood Pressure (BP) Treatment Goals Less Than 140/90 vs. Less Than 160/110 mmHg: The GOALPOST Trial

Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 4,120 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

4,120

Planned (sponsor's estimate)

Start

Sep 30, 2026

Primary completion

Dec 31, 2029

Study completion Apr 30, 2030

Sponsor

Lead sponsor
The George Washington University Biostatistics CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); University of Alabama at Birmingham; University of Utah; Brown University
First posted
Aug 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
Female only, from 14 years, up to 56 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a phase-III multi-center open-label randomized clinical trial of 4,120 individuals between 23 weeks, 0 days and 35 weeks, 6 days gestation with gestational hypertension or preeclampsia without severe features randomized to antihypertensive medication to a target blood pressure (BP) of \<140/90 mmHg or to no treatment for non-severe hypertension \< 160/110 mmHg (usual care). The primary endpoint is an adverse pregnancy composite comprised of preeclampsia with end-organ damage, medically indicated preterm delivery \<37 weeks 0 days gestation, fetal/neonatal/infant death, or placental abruption.

Conditions

  • Hypertension in Pregnancy
  • Obstetrical Complications

Interventions

  • Anti-hypertensive medication titrated to a BP goal of <140/90 mmHgDrug

    Antihypertensive medication titrated to a BP goal of \< 140/90 mmHg initiated on labetalol or nifedipine ER following standard dosing guidelines. For first line treatment with labetalol, 200 mg twice daily will be initiated and escalated to a BP goal of \<140/90 mmHg to a maximum dose of 2,400 mg/day (1,200 mg twice daily or 800 mg three times daily). If a maximum daily dose of 2,400 mg or maximal tolerated dose of labetalol is reached without achieving goal BP \<140/90 mmHg, or at provider discretion, nifedipine ER can be added as a second agent and titrated as per the nifedipine ER algorithm outlined below. For first line treatment with nifedipine ER, dosing will be initiated at 30 mg daily and escalated to a goal BP \<140/90 mmHg to a maximum dose of 120 mg/day (120 mg daily or 60 mg twice daily). If the maximum daily dose or maximal tolerated dose of nifedipine ER is reached without achieving goal BP \<140/90, or at provider discretion, labetalol can be added as described above.

  • Usual Care: Anti-hypertensive medication for BP ≥160/110 mmHg titrated to a goal of < 160/110 mmHgOther

    Usual care will not receive anti-hypertensive medication upon randomization. Participants will only be prescribed antihypertensive medication if their BP increases to ≥160/110 mmHg and titrated to a BP goal of \<160/110 mmHg. They will receive IV and/or oral anti-hypertensive medication as per local institutional protocols for management of severe range BP.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with the adverse pregnancy compositeTime frame: Randomization to 6 weeks postpartum / 6 weeks of life (a period of up to 23 weeks)

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama - Birmingham

    Birmingham, Alabama

  • Regents of the University of California San Francisco

    San Francisco, California

  • Northwestern University

    Chicago, Illinois

  • Columbia University

    New York, New York

  • University of North Carolina - Chapel Hill

    Chapel Hill, North Carolina

  • Duke University

    Durham, North Carolina

  • Case Western Reserve University

    Cleveland, Ohio

  • Ohio State University

    Columbus, Ohio

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Magee Women's Hospital

    Pittsburgh, Pennsylvania

  • Brown Univeristy

    Providence, Rhode Island

  • Baylor College of Medicine

    Houston, Texas

  • University of Texas - Houston

    Houston, Texas

  • University of Utah

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.